DelveInsight’s “Gene and Cell Therapies Targeting CNS Disorders Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gene and Cell Therapies Targeting CNS Disorders, historical and forecasted epidemiology as well as the Gene and Cell Therapies Targeting CNS Disorders market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Gene and Cell Therapies Targeting CNS Disorders market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gene and Cell Therapies Targeting CNS Disorders Market Forecast
Some of the key facts of the Gene and Cell Therapies Targeting CNS Disorders Market Report:
- The Gene and Cell Therapies Targeting CNS Disorders market size was approximately USD 1 billion in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- The United States is predicted to have the largest market for gene and cell therapies aimed at treating CNS illnesses. ZOLGENSMA had the greatest revenue in the 7MM in 2022.
- The Muscular Dystrophy Association (MDA, 2019) estimates that 15,000–20,000 Americans are currently expected to be living with ALS in the US. Amyotrophic Lateral Sclerosis (ALS) affects roughly 5 out of every 100,000 people in the US
- According to a study by Yohrling. G et al. (2020), there are currently at least 21,331 people who have been diagnosed with Huntington’s disease, but the true frequency of the disease in the US is believed to be 41,467
- A recent analysis revealed that the prevalence of MS in Europe averages 108 cases per 100,000 people, while in Italy, the prevalence is projected to be 113/100,000, with a ratio of women to males of 1.75:1. This information comes from a study by V. Perrone et al. (2022)
- Key Gene and Cell Therapies Targeting CNS Disorders Companies: Atara Biotherapeutics, Brain Neurotherapy Bio (AskBio), BrainStorm Cell Therapeutics, Corestem, Ferrer Internacional, Helixmith, Hoffmann-La Roche, Libella Gene Therapeutics, Longeveron, MeiraGTx, Voyager Therapeutics, Neurocrine Biosciences, Neuralstem, NeuroGeneration, Neuroplast, Novartis, Prevail Therapeutics (Eli Lilly and Company), Q therapeutics, Rapa Therapeutics, UniQure Biopharma, Sangamo Therapeutics, Sio Gene Therapies, StemCyte, Stemedica Cell Technologies, UniQure Biopharma, and others
- Key Gene and Cell Therapies Targeting CNS Disorders Therapies: NurOwn, AAV-GAD, VY-AADC02, ATA188, Neuro-Cells, AMT-130, and others
- The Gene and Cell Therapies Targeting CNS Disorders market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gene and Cell Therapies Targeting CNS Disorders pipeline products will significantly revolutionize the Gene and Cell Therapies Targeting CNS Disorders market dynamics.
Gene and Cell Therapies Targeting CNS Disorders Overview
The use of genetic material to cure genetic illnesses is known as gene therapy. This may entail either adding a gene’s wild-type copy or editing a gene to add a mutation to the gene’s wild-type copy. Cell therapy is the use of a patient’s own or a donor’s own cells to treat illness. Stem cells, which can develop into specialised cells, are frequently the cells employed in cell therapy.
Get a Free sample for the Gene and Cell Therapies Targeting CNS Disorders Market Report
https://www.delveinsight.com/report-store/gene-and-cell-therapies-targeting-cns-disorders-market
Gene and Cell Therapies Targeting CNS Disorders Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Gene and Cell Therapies Targeting CNS Disorders Epidemiology Segmentation:
The Gene and Cell Therapies Targeting CNS Disorders market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Gene and Cell Therapies Targeting CNS Disorders
- Prevalent Cases of Gene and Cell Therapies Targeting CNS Disorders by severity
- Gender-specific Prevalence of Gene and Cell Therapies Targeting CNS Disorders
- Diagnosed Cases of Episodic and Chronic Gene and Cell Therapies Targeting CNS Disorders
Download the report to understand which factors are driving Gene and Cell Therapies Targeting CNS Disorders epidemiology trends @ Gene and Cell Therapies Targeting CNS Disorders Epidemiology Forecast
Gene and Cell Therapies Targeting CNS Disorders Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gene and Cell Therapies Targeting CNS Disorders market or expected to get launched during the study period. The analysis covers Gene and Cell Therapies Targeting CNS Disorders market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Gene and Cell Therapies Targeting CNS Disorders Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Gene and Cell Therapies Targeting CNS Disorders Therapies and Key Companies
- NurOwn: Brainstorm Cell Therapeutics
- AAV-GAD: MeiraGTx
- VY-AADC02: Voyager Therapeutics/ NeurocrineBiosciences
- ATA188: Atara Biotherapeutics
- Neuro-Cells: Neuroplast
- AMT-130: UniQureBiopharma
Discover more about therapies set to grab major Gene and Cell Therapies Targeting CNS Disorders market share @ Gene and Cell Therapies Targeting CNS Disorders Treatment Market
Gene and Cell Therapies Targeting CNS Disorders Market Strengths
- Cell and gene therapies (CGT) are the new frontier of medicine, offering life extension and sometimes cures for previously untreatable conditions
Gene and Cell Therapies Targeting CNS Disorders Market Opportunities
- Larger firms have an edge in the gene therapy industry because they have the resources and expertise to organize intricate development pathways
Scope of the Gene and Cell Therapies Targeting CNS Disorders Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Gene and Cell Therapies Targeting CNS Disorders Companies: Atara Biotherapeutics, Brain Neurotherapy Bio (AskBio), BrainStorm Cell Therapeutics, Corestem, Ferrer Internacional, Helixmith, Hoffmann-La Roche, Libella Gene Therapeutics, Longeveron, MeiraGTx, Voyager Therapeutics, Neurocrine Biosciences, Neuralstem, NeuroGeneration, Neuroplast, Novartis, Prevail Therapeutics (Eli Lilly and Company), Q therapeutics, Rapa Therapeutics, UniQure Biopharma, Sangamo Therapeutics, Sio Gene Therapies, StemCyte, Stemedica Cell Technologies, UniQure Biopharma, and others
- Key Gene and Cell Therapies Targeting CNS Disorders Therapies: NurOwn, AAV-GAD, VY-AADC02, ATA188, Neuro-Cells, AMT-130, and others
- Gene and Cell Therapies Targeting CNS Disorders Therapeutic Assessment: Gene and Cell Therapies Targeting CNS Disorders current marketed and Gene and Cell Therapies Targeting CNS Disorders emerging therapies
- Gene and Cell Therapies Targeting CNS Disorders Market Dynamics: Gene and Cell Therapies Targeting CNS Disorders market drivers and Gene and Cell Therapies Targeting CNS Disorders market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Gene and Cell Therapies Targeting CNS Disorders Unmet Needs, KOL’s views, Analyst’s views, Gene and Cell Therapies Targeting CNS Disorders Market Access and Reimbursement
To know more about Gene and Cell Therapies Targeting CNS Disorders companies working in the treatment market, visit @ Gene and Cell Therapies Targeting CNS Disorders Clinical Trials and Therapeutic Assessment
Table of Contents
1. Gene and Cell Therapies Targeting CNS Disorders Market Report Introduction
2. Executive Summary for Gene and Cell Therapies Targeting CNS Disorders
3. SWOT analysis of Gene and Cell Therapies Targeting CNS Disorders
4. Gene and Cell Therapies Targeting CNS Disorders Patient Share (%) Overview at a Glance
5. Gene and Cell Therapies Targeting CNS Disorders Market Overview at a Glance
6. Gene and Cell Therapies Targeting CNS Disorders Disease Background and Overview
7. Gene and Cell Therapies Targeting CNS Disorders Epidemiology and Patient Population
8. Country-Specific Patient Population of Gene and Cell Therapies Targeting CNS Disorders
9. Gene and Cell Therapies Targeting CNS Disorders Current Treatment and Medical Practices
10. Gene and Cell Therapies Targeting CNS Disorders Unmet Needs
11. Gene and Cell Therapies Targeting CNS Disorders Emerging Therapies
12. Gene and Cell Therapies Targeting CNS Disorders Market Outlook
13. Country-Wise Gene and Cell Therapies Targeting CNS Disorders Market Analysis (2019–2032)
14. Gene and Cell Therapies Targeting CNS Disorders Market Access and Reimbursement of Therapies
15. Gene and Cell Therapies Targeting CNS Disorders Market Drivers
16. Gene and Cell Therapies Targeting CNS Disorders Market Barriers
17. Gene and Cell Therapies Targeting CNS Disorders Appendix
18. Gene and Cell Therapies Targeting CNS Disorders Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services